- Virax Biolabs Group Limited has signed a **Research Services Agreement (RSA)** with Emory University's Center for the Advancement of Diagnostics for a Just Society (**ADJUST Center**) to conduct clinical studies of **ViraxImmune™**.  **[1885827_20250826DA58084:0]** 
- These studies will focus on immune profiling in individuals with **post-viral syndromes**, specifically **post-acute sequelae of SARS-CoV-2 (PASC)**, commonly known as long COVID.  **[1885827_20250826DA58084:0]** 
- The collaboration aims to generate clinical data to support Virax's planned **regulatory submissions** and potential future commercial rollout of ViraxImmune™.  **[1885827_20250826DA58084:0]** 
- Virax is preparing for a **pre-submission meeting** with the U.S. Food and Drug Administration (**FDA**) in **early September 2025** to discuss the proposed intended use and regulatory pathway for ViraxImmune™ in PASC.  **[1885827_20250826DA58084:0]**

Virax Biolabs Initiates Clinical Studies for ViraxImmune™ and Prepares for FDA Pre-Submission Meeting

- Vaxxas has secured nearly **$90 million** in funding, including **$49.22 million** in Series D equity and **$40 million** in debt facilities, to accelerate the commercialization of its **high-density microarray patch (HD-MAP)** for needle-free vaccine delivery.  **[1885827_95619938b5fd42f2b59ed8458beab42c]** 
- The capital will be used to scale up production, install semi-automated manufacturing lines, and advance late-stage clinical trials, providing a financial runway into the **second half of 2027**.  **[1885827_95619938b5fd42f2b59ed8458beab42c]** 
- The company is undergoing leadership changes, with CEO David Hoey stepping down after 14 years and a global search for a new CEO underway.  **[1885827_95619938b5fd42f2b59ed8458beab42c]** 
- Vaxxas' HD-MAP technology has been administered to **more than 750 participants** across multiple clinical trials, demonstrating strong safety, tolerability, and robust immune responses.  **[1885827_95619938b5fd42f2b59ed8458beab42c]**

Virax Biolabs Group (VRAX)